Abstract
The subjective effects of two doses of cyclazocine (0.6 mg and 1.2 mg/70 kg), nalorphine (16 and 32 mg/70 kg), no-drug and placebo were compared with 32 opiate addicts using drug sensitive scales of the Addiction Research Center Inventory (ARCI) items. The effects of these narcotic antagonists were highly similar on ARCI scales and items. Both drugs produced a general drug effect, difficulty in focusing eyes, physical weakness, tiredness, poor motivation, moodiness, misery, anxiety, tension, hallucinations, changes in sensation and perception, and inefficiency of physical, cognitive and social functions. Cyclazocine was 15–26 times more potent than nalorphine. The effects of cyclazocine and nalorphine were differentiated from the effects of other drugs such as morphine, pentobarbital and LSD when the overall pattern of effect was considered.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Beecher, H. K.: Measurement of subjective responses. New York: Oxford University Press 1959.
Edwards, A. L.: Experimental design in psychological research. New York: Rinehart & Co. 1957.
Finney, D. J.: Statistical method in biological assay. New York: Hafner Publishing Co. 1952.
Fraser, H. F.: Human pharmacology and clinical uses of nalorphine (N-allynormorphine). In: The Medical Clinics of North America, pp. 1–11. Philadelphia: W. B. Saunders Company 1957.
Freedman, A. M., Fink, M., Sharoff, R., Zaks, A.: Cyclazocine and methadone in narcotic addiction. J. Amer. med. Ass. 202, 191–194 (1967).
— — — —: Clinical studies of cyclazocine in the treatment of narcotic addiction. Amer. J. Psychiat. 124, 1499–1504 (1968).
Haertzen, C. A.: Subjective drug effects: A factorial representation of subjective drug effects on the Addiction Research Center Inventory. J. nerv. ment. Dis. 140, 280–289 (1965).
—: Development of scales based on patterns of drug effects, using the Addiction Research Center Inventory (ARCI). Psychol. Rep. 18, 163–194 (1966).
—, Fuller, G.: Subjective effects of acute withdrawal of alcohol as measured by the Addiction Research Center (ARCI). Quart. J. Stud. Alcohol 28, 454–467 (1967).
—, Hill, H. E.: Assessing subjective effects of drugs: an index of carelessness and confusion for use with the Addiction Research Center Inventory (ARCI). J. clin. Psychol. 19, 407–412 (1963).
— —, Belleville, R. E.: Development of the Addiction Research Center Inventory (ARCI): Selection of items that are sensitive to the effects of various drugs. Psychopharmacologia 4, 155–166 (1963).
—, Hooks, N. T., Jr.: Changes in personality and subjective experience associated with the chronic administration and withdrawal of opiates. J. nerv. ment. Dis. 148, 606–614 (1969).
Harris, L. S., Pierson, A. K.: Some narcotic antagonists in the benzomorphan series. J. Pharmacol. exp. Ther. 143, 141–156 (1964).
Hart, E. R., McCawley, E. L.: The pharmacology of N-allynormorphine as compared with morphine. J. Pharmacol. exp. Ther. 82, 339–348 (1944).
Hart, H. E., Haertzen, C. A., Wolbach, A. B., Jr., Miner, E. J.: The Addiction Research Center Inventory: Standardization of scales which evaluate subjective effects of morphine, amphetamine, pentobarbital, alcohol, LSD-25, pyrahexyl and chlorpromazine. Psychopharmacologia (Berl.) 4, 167–183 (1963).
Isbell, H.: Nalline-a specific narcotic antagonist. Merck Rep. 62, 23–26 (1953).
Jasinski, D. R.: Narcotic antagonists as analgesics of low dependence liability-theoretical and practical implications of recent studies. In: Yearbook of drug abuse (in press).
—, Martin, W. R., Sapira, J. D.: Antagonism of the subjective, behavioral, pupillary, and respiratory depressant effects of cyclazocine by naloxone. Clin. Pharmacol. Ther. 9, 215–222 (1968).
Keats, A. S., Telford, Jane: Narcotic antagonists as analgesics. Advanc. Chemi. Ser. 45, 170–176 (1964).
Lasagna, L.: Nalorphine (N-allylnormorphine): practical and theoretical considerations. Arch. intern. Med. 94, 532–558 (1954).
—, Beecher, H. K.: The analgesic effectiveness of nalorphine and nalorphine-morphine combinations in man. J. Pharmacol. exp. Ther. 112, 356–363 (1954).
—, Dekornfeld, T. J., Pearson, J. W.: The analgesic efficacy and respiratory effects in man of a benzomorphan “narcotic antagonist”. J. Pharmacol. exp. Ther. 144, 12–16 (1964).
Martin, W. R., Fraser, H. F., Gorodetzky, C. W., Rosenberg, D. E.: Studies of the dependence-producing potential of the narcotic antagonist 2-cyclopropylmethyl-2′-hydroxy-5, 9-dimethyl-6, 7-benzomorphan (cyclazocine, Win-20, 740, ARC II-C-3). J. Pharmacol. exp. Ther. 150, 426–436 (1965).
—, Gorodetzky, C. W.: Demonstration of tolerance to and physical dependence on N-allylnormorphine (nalorphine). J. Pharmacol. exp. Ther. 150, 437–442 (1965).
— —: Cyclazocine, an adjunct in the treatment of narcotic addiction. Int. J. Addict. 2, 85–93 (1967).
— —, McClane, T. K.: An experimental study in the treatment of narcotic addicts with cyclazocine. Clin. Pharmacol. Ther. 7, 455–465 (1966).
Sollman, T.: A manual of pharmacology, 8th Ed. Philadelphia: W. B. Saunders Co. 1957.
Unna, K.: Antagonistic effect of N-allylnormorphine upon morphine. J. Pharmacol. exp. Ther. 79, 27–36 (1943).
Wikler, A., Eraser, H. F., Isbell, H.: N-allylnormorphine: Effects of single doses and precipitation of acute “abstinence syndromes” during addiction to morphine, methadone or heroin in man (postaddicts). J. Pharmacol. exp. Ther. 100, 8–20 (1953).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Haertzen, C.A. Subjective effects of narcotic antagonists cyclazocine and nalorphine on the Addiction Research Center Inventory (ARCI). Psychopharmacologia 18, 366–377 (1970). https://doi.org/10.1007/BF00402763
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00402763